Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
AOD-9604 specifically targets fat metabolism without affecting blood sugar or insulin pathways, making it theoretically useful for patients who experience gastrointestinal side effects from GLP-1 medications like Semaglutide
They were able to contact 16 of the 17 patients to assess their outcomes, with most having received their injection 6 months to 1 year before the follow-up survey
The intention is also to allow the peptide to come directly in contact with the gut lining
Laboratories remain responsible for internal validation, controlled handling, recordkeeping, and compliance procedures associated with the material after receipt
US$ 27.42
US$ 28.05
US$ 21.57
